ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.190
+0.050 (4.39%)
At close: Jul 2, 2026, 4:00 PM EDT
1.210
+0.020 (1.68%)
After-hours: Jul 2, 2026, 7:34 PM EDT
ADC Therapeutics Employees
As of December 31, 2025, ADC Therapeutics had 193 total employees, including 188 full-time and 5 part-time employees. The number of employees decreased by 72 or -27.17% compared to the previous year.
Employees
193
Change (1Y)
-72
Growth (1Y)
-27.17%
Revenue / Employee
$410,233
Profits / Employee
-$709,788
Market Cap
151.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 193 | -72 | -27.17% | 188 | 5 |
| Dec 31, 2024 | 265 | -9 | -3.28% | 263 | 2 |
| Dec 31, 2023 | 274 | -43 | -13.56% | 273 | 1 |
| Dec 31, 2022 | 317 | 5 | 1.60% | 317 | 0 |
| Dec 31, 2021 | 312 | 104 | 50.00% | 312 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Agenus | 81 |
| Connect Biopharma Holdings | 64 |
| Pyxis Oncology | 56 |
| Jyong Biotech | 27 |
| Unicycive Therapeutics | 22 |
| TuHURA Biosciences | 22 |
| AN2 Therapeutics | 21 |
ADCT News
- 1 day ago - ADC Therapeutics Announces New Employee Inducement Grant - PRNewsWire
- 3 days ago - ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial - TheFly
- 3 days ago - ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial - PRNewsWire
- 9 days ago - ADC Therapeutics to reduce workforce by 17% globally - TheFly
- 9 days ago - ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities - PRNewsWire
- 25 days ago - ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 4 weeks ago - ADC Therapeutics price target lowered to $5 from $8 at Stephens - TheFly
- 4 weeks ago - ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters